| Literature DB >> 35280458 |
Yuan Xue1,2, Bridget Hwang3, Shipan Wang1,2, Songhao Jia1,2, Haiyang Li1,2, Hongjia Zhang1,2, Wenjian Jiang1,2.
Abstract
Background: Preoperative reduced left ventricular ejection fraction (LVEF) is a prognostic factor for postoperative mortality following cardiovascular surgery. We investigated the relationship between the LVEF and the outcome of total arch replacement (TAR) in patients with subacute/chronic type A aortic dissection (TAAD).Entities:
Keywords: Subacute/chronic type A aortic dissection (subacute/chronic TAAD); left ventricular ejection fraction (LVEF); mid-term outcome; total arch replacement (TAR)
Year: 2022 PMID: 35280458 PMCID: PMC8902123 DOI: 10.21037/jtd-21-1905
Source DB: PubMed Journal: J Thorac Dis ISSN: 2072-1439 Impact factor: 2.895
Figure 1Flow chart of the screening and enrollment of study patients. TAAD, type A aortic dissection.
Figure 2Images of transthoracic echocardiography. The aortic dissection involved the ascending aorta (white arrows). LV, left ventricle; LA, left atrium; AAo, ascending aorta.
Baseline characteristics of participants
| Patient demographics | Total N=136 | 1st quartile (N=29) | 2nd quartile (N=28) | 3rd quartile (N=35) | 4th quartile (N=44) | P value |
|---|---|---|---|---|---|---|
| LVEF, % | – | <55 | 55–58 | 59–62 | >62 | – |
| Age, years | 48.1±12.7 | 45.1±11.4 | 48.2±11.0 | 44.8±10.3 | 51.7±10.3 | 0.02* |
| BMI | 25.4±3.9 | 25.0±4.4 | 25.2±2.8 | 25.9±4.9 | 25.2±3.2 | 0.87 |
| Sex (male) | 106 (77.9%) | 23 (79.3%) | 20 (71.4%) | 26 (74.3%) | 37 (84.1%) | 0.58 |
| Time of onset, days | 30.0 (20.0–90.0) | 30.0 (30.0–90.0) | 30.0 (27.5–60.0) | 30.0 (19.5–90.0) | 55.0 (20.8–135.0) | 0.16 |
| Hypertension | 84 (61.8%) | 14 (48.3%) | 14 (50.0%) | 25 (71.4%) | 31 (70.5%) | 0.84 |
| Smoking | 70 (51.5%) | 16 (55.2%) | 15 (53.6%) | 14 (40.0%) | 25 (56.8%) | 0.21 |
| Diabetes | 8 (5.9%) | 2 (6.9%) | 1 (3.6%) | 2 (5.7%) | 3 (6.8%) | 0.94 |
| History of cerebrovascular disease | 5 (3.7%) | 0 (0.0%) | 0 (0.0%) | 2 (5.7%) | 3 (6.8%) | 0.28 |
| Marfan syndrome | 3 (2.2%) | 1 (3.4%) | 0 (0.0%) | 1 (2.9%) | 1 (2.3%) | 0.82 |
| History of cardiovascular disease | 28 (20.6%) | 4 (13.8%) | 3 (10.7%) | 10 (28.6%) | 11 (25.0%) | 0.22 |
| History of cardiac surgery | 12 (8.8%) | 3 (10.3%) | 0 (0.0%) | 4 (11.4%) | 5 (11.4%) | 0.33 |
| History of TEVAR | 8 (5.9%) | 0 (0.0%) | 1 (3.6%) | 3 (8.6%) | 4 (9.1%) | 0.34 |
| Coronary artery disease | 10 (7.4%) | 0 (0.0%) | 2 (7.1%) | 4 (11.4%) | 4 (9.1%) | 0.34 |
| Left ventricular end diastolic diameter, mm | 54.4±9.6 | 60.9±9.0 | 57.5±9.5 | 51.7±9.3 | 50.3±7.2 | <0.01* |
| Left ventricular end systolic diameter, mm | 37.5±9.4 | 46.6±10.1 | 40.2±8.6 | 34.7±7.1 | 31.9±4.9 | <0.01* |
| Ascending aorta diameter, mm | 52.5±12.3 | 54.9±14.2 | 54.1±14.8 | 46.8±8.8 | 45.1±9.1 | <0.01* |
| Aortic regurgitation | 0.02* | |||||
| Mild | 43 (31.6%) | 4 (13.8%) | 10 (35.7%) | 11 (31.4%) | 18 (40.9%) | |
| Moderate | 14 (10.3%) | 5 (17.2%) | 3 (10.7%) | 5 (14.3%) | 1 (2.3%) | |
| Severe | 39 (28.7%) | 13 (44.8%) | 11 (39.3%) | 7 (20.0%) | 8 (18.2%) | |
| Mitral regurgitation | 0.29 | |||||
| Mild | 50 (36.8%) | 11 (37.9%) | 11 (39.3%) | 13 (37.1%) | 15 (34.1%) | |
| Moderate | 5 (3.7%) | 3 (10.3%) | 1 (3.6%) | 1 (2.9%) | 0 (0.0%) | |
| Severe | 3 (2.2%) | 2 (6.9%) | 0 (0.0%) | 0 (0.0%) | 1 (2.3%) |
Results are expressed as n (%) or mean ± standard deviation or median interquartile range. *, P<0.05. BMI, body mass index; TEVAR, thoracic endovascular aortic repair; LVEF, left ventricular ejection fraction.
Operative details and postoperative outcomes
| Operative details | Total N=136 | 1st quartile (N=29) | 2nd quartile (N=28) | 3rd quartile (N=35) | 4th quartile (N=44) | P value |
|---|---|---|---|---|---|---|
| Bentall procedure | 60 (44.1%) | 17 (58.6%) | 17 (60.7%) | 12 (34.3%) | 14 (31.8%) | 0.02* |
| Coronary artery bypass grafting | 11 (8.1%) | 4 (13.8%) | 2 (7.1%) | 2 (5.7%) | 3 (6.8%) | 0.65 |
| Mitral valve repair/replacement | 5 (3.7%) | 5 (17.2%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | <0.01* |
| Tricuspid valve repair/replacement | 1 (0.7%) | 0 (0.0%) | 1 (3.6%) | 0 (0.0%) | 0 (0.0%) | 0.274 |
| Cardiopulmonary bypass time, min | 195.5±50.3 | 206.2±56.1 | 198.3±44.1 | 183.4±36.3 | 196.4±58.5 | 0.33 |
| Aortic cross-clamp time, min | 105.1±33.2 | 114.2±38.6 | 107.8±28.8 | 96.3±28.1 | 104.3±35.1 | 0.19 |
| Nasopharyngeal temperature, °C | 23.4±1.3 | 23.5±1.4 | 23.2±1.4 | 23.6±1.2 | 23.3±1.2 | 0.70 |
| Hypothermic circulatory arrest time, min | 25.2±9.7 | 24.0±8.0 | 26.5±10.8 | 25.7±10.4 | 24.8±9.7 | 0.76 |
| Postoperative outcomes | ||||||
| Ventilator time, hour | 40.0 (26.0–84.0) | 54.0 (38.0–132.0) | 40.5 (33.0–72.0) | 34.0 (25.0–82.0) | 38.0 (20.0–78.0) | 0.65 |
| Intensive care unit length of stay, days | 1.7 (1.0–3.1) | 2.1 (1.1–3.6) | 1.8 (1.1–3.2) | 1.4 (0.9–3.3) | 1.1 (0.9–3.0) | 0.95 |
| Hospital length of stay, days | 17.0 (12.0–23.0) | 17.0 (13.0–24.0) | 17.5 (13.8–22.2) | 14.0 (9.0–22.0) | 17.0 (13.8–22.2) | 0.34 |
| Neurological complications | 9 (6.6%) | 3 (10.3%) | 1 (3.6%) | 4 (11.4%) | 1 (2.3%) | 0.29 |
| Respiratory complications | 16 (11.8%) | 5 (17.2%) | 4 (14.3%) | 2 (5.7%) | 5 (11.4%) | 0.52 |
| Dialysis | 10 (7.4%) | 2 (6.9%) | 3 (10.7%) | 2 (5.7%) | 3 (6.8%) | 0.89 |
Results are expressed as n (%) or mean ± standard deviation or median interquartile range. *, P<0.05.
Cox proportional hazards regression analysis for risk factors of mortality
| Variables | Univariable | Multivariable | |||
|---|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | ||
| Age | 0.99 (0.95, 1.04) | 0.78 | – | – | |
| Gender (male) | 0.35 (0.12, 1.01) | 0.053 | – | – | |
| BMI | 0.91 (0.79, 1.06) | 0.23 | – | – | |
| Diabetes | 1.36 (0.18, 10.4) | 0.77 | – | – | |
| Hypertension | 1.15 (0.39, 3.44) | 0.80 | – | – | |
| History of cardiovascular disease | 1.08 (0.30, 3.88) | 0.90 | – | – | |
| History of heart surgery | 0.83 (0.11, 6.38) | 0.86 | – | – | |
| Aortic regurgitation | – | – | |||
| No | Ref | – | – | ||
| Mild | 1.37 (0.23, 8.19) | 0.73 | – | – | |
| Moderate | † | † | – | – | |
| Severe | 4.88 (1.05, 22.58) | 0.04* | 2.7 (0.54, 13.4) | 0.220 | |
| LVEF | 0.90 (0.84, 0.97) | <0.01* | 0.93 (0.86, 0.99) | 0.03* | |
| Cardiopulmonary bypass time, min | 1.01 (1.00, 1.02) | <0.01* | 1.01(1.001, 1.02) | 0.054 | |
| Hypothermic circulatory arrest time, min | 0.96 (0.91, 1.03) | 0.26 | – | – | |
| Nasopharyngeal temperature, °C | 1.39 (0.89, 2.16) | 0.15 | – | – | |
| Bentall procedure | 2.35 (0.79, 7.00) | 0.13 | – | – | |
| Coronary artery bypass grafting | 3.58 (1.00, 12.84) | 0.05 | – | – | |
†, the result failed because of the small sample size; *, P<0.05. CI, confidence interval; HR, hazards ratio; BMI, body mass index; LVEF, left ventricular ejection fraction.
Figure 3Kaplan-Meier analysis of LVEF with the outcome of all-cause mortality by quartiles. The colored lines represent the quartiles of LVEF levels. The log-rank P values and number of participants within each category are shown. LVEF, left ventricular ejection fraction.
Figure 4Kaplan-Meier analysis for full study cohort, stratified by LVEF ≥55% and LVEF <55%. Log-rank P values and number of participants within each category are shown. LVEF, left ventricular ejection fraction.